ESMO/LinkedIn
May 16, 2025, 17:42
APHINITY Trial Update Shows OS Benefit with Pertuzumab in HER2+ Breast Cancer – ESMO
European Society for Medical Oncology (ESMO) shared a post on LinkedIn:
“As presented as a late-breaker at ESMO Breast 2025, a prespecified long-term analysis of the APHINITY phase III trial (median follow-up 11.3 years) revealed a significant improvement in overall survival (OS) with the addition of adjuvant pertuzumab to trastuzumab plus chemotherapy in patients with HER2+ operable Breast Cancer.
The OS benefit with pertuzumab was found in patients with node-positive but not node-negative disease. Improved invasive disease-free survival was also maintained. Read the results and commentary in the ESMO Daily Reporter.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 17:56
May 16, 2025, 17:35
May 16, 2025, 16:47
May 16, 2025, 16:35